CR20230193A - Derivados de pirazol como inhibidores de la ret-cinasa - Google Patents

Derivados de pirazol como inhibidores de la ret-cinasa

Info

Publication number
CR20230193A
CR20230193A CR20230193A CR20230193A CR20230193A CR 20230193 A CR20230193 A CR 20230193A CR 20230193 A CR20230193 A CR 20230193A CR 20230193 A CR20230193 A CR 20230193A CR 20230193 A CR20230193 A CR 20230193A
Authority
CR
Costa Rica
Prior art keywords
kinase inhibitors
pyrazole derivatives
ret kinase
compounds
formula
Prior art date
Application number
CR20230193A
Other languages
English (en)
Inventor
Megan L Mckenney
Erin D Anderson
Thomas C Irvin
Gabrielle R A/K/A Jody Gabrielle Rustmann Kolakowski Kolakowski
Kevin R Condroski
Elizabeth A Mcfaddin
Steven W Andrews
Christopher Pierre Albert Jean Boldron
Manoj Kumar
Thomas Pierre Dino Pancaldi
Marta Pinto
Johnathan Alexander Mclean
Tiphaine Mouret
Michael J Munchhof
Michael Alexander Pilkington-Miksa
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20230193A publication Critical patent/CR20230193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente descripción se describen compuestos de Fórmula I: o una sal farmacéuticamente aceptable de este, donde las variables son como se definen en la presente descripción. Estos compuestos son útiles en el tratamiento de cánceres asociados a RET. También se describen formulaciones que contienen los compuestos de Fórmula I y métodos para preparar los compuestos de Fórmula I.
CR20230193A 2020-11-06 2021-11-05 Derivados de pirazol como inhibidores de la ret-cinasa CR20230193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063110643P 2020-11-06 2020-11-06
PCT/US2021/058206 WO2022098970A1 (en) 2020-11-06 2021-11-05 Pyrazole derivatives asr et kinase inhibitors

Publications (1)

Publication Number Publication Date
CR20230193A true CR20230193A (es) 2023-07-03

Family

ID=78806726

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230193A CR20230193A (es) 2020-11-06 2021-11-05 Derivados de pirazol como inhibidores de la ret-cinasa

Country Status (18)

Country Link
US (2) US11697647B2 (es)
EP (1) EP4240738A1 (es)
JP (2) JP7338072B2 (es)
KR (1) KR20230104146A (es)
CN (1) CN116438179A (es)
AR (1) AR124007A1 (es)
AU (1) AU2021376367A1 (es)
CA (1) CA3197032A1 (es)
CL (1) CL2023001277A1 (es)
CO (1) CO2023005600A2 (es)
CR (1) CR20230193A (es)
DO (1) DOP2023000088A (es)
EC (1) ECSP23033180A (es)
IL (1) IL302542A (es)
MX (1) MX2023005289A (es)
PE (1) PE20231984A1 (es)
TW (2) TWI790810B (es)
WO (1) WO2022098970A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20230193A (es) * 2020-11-06 2023-07-03 Lilly Co Eli Derivados de pirazol como inhibidores de la ret-cinasa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105051027A (zh) * 2013-03-15 2015-11-11 葛兰素史密斯克莱知识产权发展有限公司 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
WO2020035065A1 (zh) 2018-08-17 2020-02-20 南京明德新药研发有限公司 作为ret抑制剂的吡唑衍生物
AR121914A1 (es) * 2020-04-27 2022-07-20 Lilly Co Eli Compuestos útiles para inhibir la quinasa ret
CR20230193A (es) * 2020-11-06 2023-07-03 Lilly Co Eli Derivados de pirazol como inhibidores de la ret-cinasa

Also Published As

Publication number Publication date
JP7338072B2 (ja) 2023-09-04
AU2021376367A1 (en) 2023-05-11
ECSP23033180A (es) 2023-06-30
TW202315623A (zh) 2023-04-16
EP4240738A1 (en) 2023-09-13
AR124007A1 (es) 2023-02-01
TW202233180A (zh) 2022-09-01
CN116438179A (zh) 2023-07-14
JP2023099116A (ja) 2023-07-11
MX2023005289A (es) 2023-07-26
US11697647B2 (en) 2023-07-11
TWI790810B (zh) 2023-01-21
AU2021376367A9 (en) 2023-07-13
DOP2023000088A (es) 2023-07-16
IL302542A (en) 2023-07-01
JP2023504303A (ja) 2023-02-02
PE20231984A1 (es) 2023-12-12
US11970485B2 (en) 2024-04-30
WO2022098970A9 (en) 2023-04-27
WO2022098970A1 (en) 2022-05-12
US20220144816A1 (en) 2022-05-12
CO2023005600A2 (es) 2023-05-29
CA3197032A1 (en) 2022-05-12
CL2023001277A1 (es) 2023-12-01
KR20230104146A (ko) 2023-07-07
US20230265085A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
MX2021014096A (es) Compuestos heterociclicos, metodos de preparacion y usos de estos.
AU2024202573A1 (en) KRas G12C inhibitors
GEP20227433B (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
NZ796075A (en) Five-membered heteroaromatic imidazole compound and use thereof
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
MX2020007265A (es) Derivados de rapamicina.
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
MX2022013657A (es) Quimioterápicos de éter macrocíclico heteroaromático.
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2021012105A (es) Compuestos de pirrol.
CR20230193A (es) Derivados de pirazol como inhibidores de la ret-cinasa
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
MX2023000333A (es) Sales y formas de un inhibidor wee1.
MX2021009206A (es) Terapias contra el cancer.